Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Total Non-Current Liabilities (2022 - 2025)

Heron Therapeutics' Total Non-Current Liabilities history spans 4 years, with the latest figure at $236.7 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 11.06% year-over-year to $236.7 million; the TTM value through Dec 2025 reached $236.7 million, down 11.06%, while the annual FY2025 figure was $236.7 million, 11.06% down from the prior year.
  • Total Non-Current Liabilities reached $236.7 million in Q4 2025 per HRTX's latest filing, up from $229.4 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $266.2 million in Q4 2024 to a low of $229.4 million in Q3 2025.
  • Average Total Non-Current Liabilities over 4 years is $250.6 million, with a median of $253.6 million recorded in 2024.
  • Peak YoY movement for Total Non-Current Liabilities: rose 8.34% in 2024, then dropped 11.96% in 2025.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $237.1 million in 2022, then increased by 8.05% to $256.2 million in 2023, then grew by 3.88% to $266.2 million in 2024, then fell by 11.06% to $236.7 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Total Non-Current Liabilities are $236.7 million (Q4 2025), $229.4 million (Q3 2025), and $258.6 million (Q2 2025).